News & Articles

The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was imple
Read More
Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK - 20th F
Read More
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for O
Read More
The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix Oxford, UK - 16th Janu
Read More
Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Pre
Read More
Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK - 13th December 2024
Read More
en_GBEnglish